When should a second vasopressor be added if norepinephrine (Levophed) is being infused at 0.25 µg/kg/min and the target mean arterial pressure cannot be maintained?

When to Add a Second Vasopressor to Norepinephrine

Add a second vasopressor (either vasopressin 0.03 U/min or epinephrine) when norepinephrine alone fails to achieve your target MAP of 65 mmHg, rather than waiting for any specific dose threshold like 0.25 mcg/kg/min. 1

The Guideline-Based Approach

The Surviving Sepsis Campaign 2016 guidelines do not specify a particular norepinephrine dose at which to add a second agent 1. Instead, the recommendation is straightforward:

• First-line: Norepinephrine (strong recommendation)
• Second-line options when MAP target not achieved:
  • Add vasopressin (up to 0.03 U/min) to raise MAP to target OR to decrease norepinephrine requirements (weak recommendation, moderate quality evidence)
  • Add epinephrine (weak recommendation, low quality evidence)

Practical Decision-Making Algorithm

Step 1: Ensure Adequate Fluid Resuscitation First

Before escalating vasopressors, confirm the patient has received appropriate fluid resuscitation (minimum 30 mL/kg crystalloids) 1. Occult hypovolemia is a common reason for apparent vasopressor resistance 2.

Step 2: Target MAP of 65 mmHg Initially

Start with a MAP goal of 65 mmHg for most patients 1. In previously hypertensive patients, consider targeting no more than 40 mmHg below their baseline systolic pressure 2.

Step 3: Add Second Vasopressor Based on Clinical Response, Not Arbitrary Dose

The critical decision point is inadequate MAP response, not reaching 0.25 mcg/kg/min. Recent evidence suggests:

• If you cannot achieve MAP ≥65 mmHg within 60 minutes of norepinephrine initiation, this is associated with increased ICU mortality 3
• Earlier addition of vasopressin (within 3 hours of starting norepinephrine) leads to faster shock resolution compared to late addition 4
• Continuing to escalate norepinephrine alone in refractory shock may increase catecholamine-related complications without improving outcomes 5, 6

Step 4: Choose Your Second Agent

Vasopressin (preferred in most cases):

• Dose: 0.03 U/min (fixed dose, not titrated) 1
• Advantages: Non-adrenergic mechanism, may preserve renal perfusion, reduces norepinephrine requirements
• Add when norepinephrine alone is insufficient, ideally early rather than waiting for very high doses 4, 5

Epinephrine (alternative):

• Consider when additional inotropic support may be beneficial
• Has both vasopressor and inotropic effects 1

Critical Pitfalls to Avoid

1. Don't wait for arbitrary high norepinephrine doses: The 0.25 mcg/kg/min threshold you mention has no guideline support. If MAP remains inadequate despite adequate fluid resuscitation and moderate norepinephrine doses, add a second agent rather than continuing to escalate 7, 5, 6.

2. Don't ignore occult hypovolemia: Patients requiring very high vasopressor doses often have unrecognized volume depletion. Central venous pressure monitoring can help identify this 2.

3. Don't use dopamine for renal protection: This is explicitly not recommended 1.

4. Don't delay arterial line placement: All patients on vasopressors should have an arterial catheter placed as soon as practical 1.

The Evidence on Timing

Emerging data increasingly supports earlier addition of a second vasopressor rather than aggressive norepinephrine escalation:

• Failure to achieve MAP ≥65 mmHg within 60 minutes independently predicts mortality 3
• Early vasopressin addition (<3 hours) reduces time to shock resolution by approximately 23 hours compared to late addition 4
• High-dose norepinephrine (≥1 mcg/kg/min) carries risks of arrhythmias, ischemia, and excessive vasoconstriction that may worsen tissue perfusion despite adequate MAP 8, 7, 5, 6

In practice, consider adding vasopressin when norepinephrine reaches approximately 0.1-0.2 mcg/kg/min and MAP remains below target, rather than waiting to reach or exceed 0.25 mcg/kg/min. This approach balances the need for adequate perfusion pressure against the risks of excessive catecholamine exposure 5, 6.